| Lo Eye Care | |
|
1200 E Michigan Ave, Suite 110, Lansing, MI 48912-1800 | |
| (517) 364-5875 | |
| (517) 364-5877 |
| Full Name | Lo Eye Care |
|---|---|
| Type | Facility |
| Speciality | Ophthalmology |
| Location | 1200 E Michigan Ave, Lansing, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063544484 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Secondary |
| 207W00000X | Ophthalmology | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lo Eye Care 1005 Charlevoix Dr Ste 100, Grand Ledge, MI 48837-8186 Ph: (517) 337-1668 | Lo Eye Care 1200 E Michigan Ave, Suite 110, Lansing, MI 48912-1800 Ph: (517) 364-5875 |
News Archive
In a step towards improving rehabilitation for patients with walking impairments, researchers from the Kennedy Krieger Institute found that non-invasive stimulation of the cerebellum, an area of the brain known to be essential in adaptive learning, helped healthy individuals learn a new walking pattern more rapidly.
Many families beat the summer heat with trips to swimming pools, beaches, and water parks; but water safety concerns are particularly heightened for families of children with autism, said Varleisha Gibbs, OTD, OTR/L, occupational therapy professor at University of the Sciences in Philadelphia.
After the collapse of negotiations between Atlanta's public hospital and the world's largest dialysis provider, a dozen immigrants suffering from renal failure were refused treatment at an Atlanta clinic on Thursday and advised to wait until their conditions deteriorated enough to justify life-saving care in an emergency room. Unless the deadlock is broken, 22 patients, most of them illegal immigrants, face a debilitating cycle.
A scientist from the Florida campus of The Scripps Research Institute has been awarded a pair of grants totaling $2.8 million from the National Institute of General Medical Sciences of the National Institutes of Health, and from TargAnox, a Massachusetts-based biotechnology firm.
Breckenridge Pharmaceutical, Inc. announced today that it has finalized its agreement with Zhejiang Huahai Pharmaceuticals Co., Ltd. (Huahai) to market Nevirapine Tablets. Nevirapine 200mg Tablets are AB rated to Viramune a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection and AIDS, which is marketed by Boehringer Ingelheim.
› Verified 9 days ago